Seroepidemiological Survey of the Antibody for Severe Acute Respiratory Syndrome Coronavirus 2 with Neutralizing Activity at Hospitals: A Cross-sectional Study in Hyogo Prefecture, Japan.
COVID-19
Hyogo
Japan
SARS-CoV-2
epidemiology
neutralizing activity
seroprevalence
Journal
JMA journal
ISSN: 2433-3298
Titre abrégé: JMA J
Pays: Japan
ID NLM: 101769797
Informations de publication
Date de publication:
29 Jan 2021
29 Jan 2021
Historique:
received:
25
10
2020
accepted:
04
12
2020
entrez:
12
2
2021
pubmed:
13
2
2021
medline:
13
2
2021
Statut:
ppublish
Résumé
The coronavirus disease 2019 (COVID-19) pandemic is spreading rapidly all over the world. The Japanese government lifted the state of emergency, announced in April 2020, on May 25, but there are still sporadic clusters. Asymptomatic patients who can transmit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cause some of these clusters. It is thus urgent to investigate the seroprevalence of antibodies against SARS-CoV-2 and their neutralizing activity. We conducted a cross-sectional study of >10,000 samples at hospitals in Hyogo Prefecture, Japan. Between August 6 and October 1, 2020, we collected samples of residual blood from the patients who visited or were admitted to five hospitals and a foundation in Hyogo. We tested the samples for antibodies against SARS-CoV-2 by electrochemiluminescence immunoassay (ECLIA) and chemiluminescent enzyme immunoassay (CLEIA). Sera that were positive by ECLIA or CLEIA were analyzed by an immunochromatographic (IC) test and neutralizing activity assay. We tested 10,377 samples from patients aged between 0 and 99 years old; 27 cases (0.26%) were positive on the ECLIA, and 51 cases (0.49%) were positive on CLEIA. In the 14 cases that tested positive on both ECLIA and CLEIA, the positive rates on the IC test and for neutralizing activity were high (85% and 92%, respectively). In 50 cases (0.48%) that were positive by either ECLIA or CLEIA, the corresponding rates were low (20% and 6%, respectively). The positive rate of neutralizing antibody was 0.15%. These results indicate that most Hyogo Prefecture residents still do not have antibodies and should avoid the risk of incurring a SARS-CoV-2 infection. Two or more antibody tests should be required for seroepidemiological studies of the antibody for SARS-CoV-2, and a neutralizing activity assay is also essential.
Identifiants
pubmed: 33575502
doi: 10.31662/jmaj.2020-0094
pmc: PMC7872787
doi:
Types de publication
Journal Article
Langues
eng
Pagination
41-49Informations de copyright
Copyright © Japan Medical Association.
Déclaration de conflit d'intérêts
Yasuko Mori received the reagents for 5,000 samples used here from Roche as a collaboration of this research.
Références
Nature. 2020 Aug;584(7821):457-462
pubmed: 32668444
Science. 2020 Dec 11;370(6522):1339-1343
pubmed: 33159009
Clin Chim Acta. 2020 Oct;509:18-21
pubmed: 32485155
JAMA. 2020 Jun 16;323(23):2425-2427
pubmed: 32421144
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
Science. 2020 Jul 10;369(6500):208-211
pubmed: 32404476
J Med Virol. 2020 Oct;92(10):1795-1796
pubmed: 32311142
Clin Infect Dis. 2020 May 31;:
pubmed: 32474577
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet. 2016 Aug 13;388(10045):728-30
pubmed: 27059886
J Infect. 2020 Sep;81(3):420-426
pubmed: 32504745
Nature. 2020 Aug;584(7821):437-442
pubmed: 32555388
JAMA Intern Med. 2020 Aug 6;:
pubmed: 32780793
Proc Natl Acad Sci U S A. 2020 Mar 31;117(13):7001-7003
pubmed: 32165541